MARKET

ANIX

ANIX

Anixa Biosciences Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.300
+0.380
+13.01%
After Hours: 3.270 -0.03 -0.91% 19:47 07/10 EDT
OPEN
3.300
PREV CLOSE
2.920
HIGH
3.520
LOW
3.100
VOLUME
2.87M
TURNOVER
--
52 WEEK HIGH
5.45
52 WEEK LOW
1.330
MARKET CAP
77.62M
P/E (TTM)
-7.1802
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ANIX stock price target is 8.75 with a high estimate of 9.00 and a low estimate of 8.50.

EPS

ANIX News

More
The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergan's Botox Gets Label Expansion, 3 IPOs
Benzinga · 2d ago
NIO, HMY among premarket gainers
Seeking Alpha - Article · 2d ago
Anixa nabs European patent covering CAR-T technology
Seeking Alpha - Article · 2d ago
The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergan's Botox Gets Label Expansion, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 9) Affimed NV (NASDAQ: AFMD)
Benzinga · 2d ago
Anixa Biosciences' CAR-T Cancer Therapy Receives Intention To Grant Notice From European Patent Office
SAN JOSE, Calif., July 10, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the European
Benzinga · 2d ago
Anixa Biosciences' CAR-T Cancer Therapy Receives Intention to Grant Notice from the European Patent Office
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the European Patent Office has issued an Intention to Grant notice for the first European patent cov
PR Newswire · 2d ago
Anixa and OntoChem identify potential COVID-19 candidates
Seeking Alpha - Article · 6d ago
Anixa and OntoChem complete initial screening program and identification of additional COVID-19 compounds
Seeking Alpha - Article · 6d ago

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About ANIX

Anixa Biosciences, Inc. is a biotechnology company. The Company is developing a cancer immunotherapy program, which leverages chimeric endocrine receptor t-cell (CER-T) technology, and is engaged in developing a diagnostic platform called Cchek, for the early detection of tumor-based cancers. The Cchek liquid biopsy technology is a series of non-invasive blood tests for early detection of solid tumors based on the body's immune response to a malignancy by detecting the presence, absence and quantity of certain immune cells that exist in and around a tumor and that enter the blood stream. This technology enables cancer detection in its earliest stages in efforts to treat patients when the disease is curable. The Company has developed techniques and protocols for measuring the subtle immunological changes that occur in the blood stream during tumor development. Through its protocols, the Company has detected the biomarkers in the peripheral blood of biopsy verified cancer patients.
More

Webull offers kinds of Anixa Biosciences Inc stock information, including NASDAQ:ANIX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANIX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ANIX stock methods without spending real money on the virtual paper trading platform.